BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10812	Companies
234229	Keywords
163015	Articles
125238	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 06/11/2026 at 00:30, 1 month 26 days ago

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
BioNxt Solutions Inc. announces amendment of terms for unsecured convertible debentures, extending maturity dates and issuing common share purchase warrants. For further details, visit bionxt.com

BioNxt Solutions Inc. Common Share Purchase Warrants Regulatory Approvals Debentures Maturity Dates
BRIEF

published on 05/19/2026 at 09:10, 2 months 19 days ago

BioNxt progresse dans le développement d'un film orodispersible de sémaglutide

Développement Pharmaceutique Solutions BioNxt Thérapies GLP-1 Administration Sublinguale De Médicaments Semaglutide ODF
BRIEF

published on 05/19/2026 at 09:10, 2 months 19 days ago

BioNxt Progresses in Semaglutide Oral Dissolvable Film Development

Pharmaceutical Development BioNxt Solutions GLP-1 Therapies Sublingual Drug Delivery Semaglutide ODF
PRESS RELEASE

published on 05/19/2026 at 09:05, 2 months 19 days ago

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
BioNxt Solutions Inc. announces advancement of Semaglutide oral dissolvable film program into active pharmaceutical development phase, targeting growing GLP-1 market. Company leverages expertise in drug delivery systems for chronic diseases

BioNxt Solutions Inc. Oral Dissolvable Film Drug Delivery Systems Semaglutide GLP-1 Market
BRIEF

published on 04/28/2026 at 09:10, 3 months 9 days ago

BioNxt Explores Psychedelic Drug Delivery Advances

Drug Delivery Technology Mental Health Treatments BioNxt Solutions Regulatory Developments Psychedelic Therapeutics
BRIEF

published on 04/28/2026 at 09:10, 3 months 9 days ago

BioNxt explore les avancées en matière d'administration de drogues psychédéliques

Technologie D'administration De Médicaments Solutions BioNxt Évolutions Réglementaires Thérapie Psychédélique Traitements De Santé Mentale
PRESS RELEASE

published on 04/28/2026 at 09:05, 3 months 9 days ago

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
BioNxt Solutions Inc. is exploring applying its drug delivery tech to psychedelic therapeutics amid global momentum. Market opportunity in mental health treatments highlighted

BioNxt Solutions Inc. Mental Health Disorders Drug Delivery Technologies Psychedelic Therapeutics Advanced Drug Delivery
BRIEF

published on 04/14/2026 at 09:10, 3 months 23 days ago

BioNxt Commences GMP Manufacturing for Multiple Sclerosis Treatment

Clinical Trials Multiple Sclerosis GMP Manufacturing BioNxt Solutions Sublingual Cladribine
BRIEF

published on 04/14/2026 at 09:10, 3 months 23 days ago

BioNxt lance la production conforme aux BPF pour le traitement de la sclérose en plaques

Essais Cliniques Sclérose En Plaques Solutions BioNxt Cladribine Sublinguale Fabrication Conforme Aux BPF
PRESS RELEASE

published on 04/14/2026 at 09:05, 3 months 23 days ago

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
BioNxt announces successful completion of GMP manufacturing for sublingual Cladribine oral thin film, advancing to clinical-stage execution. Company aims to treat MS and neurodegenerative diseases

GMP Manufacturing Sublingual Cladribine MS Treatment BioNxt Clinical-stage Execution

Accesswire

Published on 08/07/2026 at 14:17, 6 hours 1 minute ago

NuRAN Wireless Increases Series A Preferred Share Financing to C$7.6 Million and Announces Debt Settlements
Published on 08/07/2026 at 13:00, 7 hours 18 minutes ago

Gold Terra Announces Start of Drilling on the Campbell Shear Northern Zone 103N Extension to Expand 2026 MRE of Inferred 595,000 Ounces, Con Mine, Yellowknife, NWT
Published on 08/07/2026 at 00:45, 19 hours 33 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 21 hours 3 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 22 hours 3 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 19:30, 48 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 1 hour 3 minutes ago

ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 2 hours 8 minutes ago

Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:00, 2 hours 18 minutes ago

E-PANGO: Composition du capital au 31 juillet 2026
Published on 08/07/2026 at 17:45, 2 hours 33 minutes ago

Schroder ETFs ICAV: Publication of the Audited Annual Report for Switzerland

Les Echos

Published on 08/07/2026 at 18:54, 1 hour 24 minutes ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 hour 24 minutes ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 hour 38 minutes ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 1 hour 38 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 2 hours 18 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE